Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 05 2017 - 4:05PM
Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company
focused on improving patients’ lives by identifying, developing,
acquiring and commercializing differentiated and accessible
medicines that address unmet medical needs, today announced that
the compensation committee of its board of directors approved the
grant on Dec. 1, 2017 of inducement restricted stock units for an
aggregate of 112,552 ordinary shares and inducement stock options
for an aggregate of 28,599 ordinary shares to 30 new employees.
Each restricted stock unit vests over four years, with 25
percent of the shares vesting on each anniversary of the applicable
vesting commencement date, subject to the new employee's continued
service relationship with the Company. Each restricted stock
unit also is subject to the terms and conditions of the Company's
2014 Equity Incentive Plan and the restricted stock unit agreement
pursuant to which the restricted stock unit was granted.
Each stock option has an exercise price per share equal to
$14.33, the fair market value on the grant date, and vests over
four years, with 25 percent of the shares vesting on the one-year
anniversary of the applicable vesting commencement date and 1/48 of
the shares vesting monthly thereafter, subject to the new
employee's continued service relationship with the Company.
Each stock option also has a 10-year term and is subject to the
terms and conditions of the Company's 2014 Equity Incentive Plan
and the stock option agreement pursuant to which the option was
granted.
The restricted stock units and stock options were granted as
inducements material to the new employees entering into employment
with Horizon Pharma in accordance with NASDAQ Listing Rule
5635(c)(4).
About Horizon Pharma plcHorizon Pharma plc is a
biopharmaceutical company focused on improving patients' lives by
identifying, developing, acquiring and commercializing
differentiated and accessible medicines that address unmet medical
needs. The Company markets 11 medicines through its orphan,
rheumatology and primary care business units. For more
information, please visit www.horizonpharma.com. Follow
@HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts:Tina VenturaSenior Vice President,
Investor RelationsInvestor-relations@horizonpharma.com
Ruth VenningExecutive Director, Investor
RelationsInvestor-relations@horizonpharma.com
U.S. Media Contact:Geoffrey CurtisSenior Vice President,
Corporate Affairs and Chief Communications
Officermedia@horizonpharma.com
Ireland Media Contact: Ray Gordon Gordon MRM
ray@gordonmrm.ie
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2023 to Apr 2024